Release date: 2016-03-16
The 2016 IBM Forum on the theme of "Welcome to the Cognitive Era, IBM and Your Wisdom for the Future" was successfully held in Beijing. At the meeting, Chen Liming, Chairman of IBM Greater China, announced that IBM's cognitive business strategy has officially landed in China. Cognitive business is another major transformation strategy released by IBM after the “Smart Earthâ€, which will trigger another wave of business transformation comparable to e-commerce. At the forum, IBM introduced the latest achievements of cognitive business in China, including the latest cooperation with local partners such as Pfizer China and HKUST.
As the world's largest R&D-based biopharmaceutical company, Pfizer has teamed up with IBM China to jointly develop cutting-edge medical institutions, using big data and new cognitive analysis methods to establish a chronic disease risk prediction model that meets the characteristics of the Chinese population. Key risk factors accelerate the process of scientific discovery. With this disease risk prediction model and clinical decision support system, doctors expect to greatly improve the quality of diagnosis and treatment, and propose personalized diagnosis and treatment recommendations for individual patients, saving patients' medical costs. The popularity of this model will help to improve the level of evidence-based diagnosis and treatment in community hospitals, thus alleviating the pressure of hospital visits in the top three hospitals, and providing support for promoting China's graded diagnosis and treatment and achieving intelligent medical transformation and upgrading.
Dr. Gu Chengming, Vice President of Pfizer China Medical Department, said: "In recent years, many countries are facing increasingly serious chronic disease challenges. The application and promotion of cognitive technologies will help improve the accuracy and efficiency of chronic disease diagnosis and treatment. Through IBM and many leading medical treatments in China. The cross-disciplinary cooperation and innovation of the organization will benefit the majority of patients and families suffering from chronic diseases. We can already see the innovative opportunities that cognitive technology brings to this industry, and look forward to the future to promote more collaborative innovation. A breakthrough in the field of high-tech medicine."
After the meeting, Dr. Gu Chengming, Vice President of Pfizer China Medical Department and Xie Guobiao, Director of Cognitive Medical Research at IBM China Research Institute, accepted an interview.
Question: What is the development of the medical industry in the practice field of the “cognitive era�
Xie Guozhen : The "cognitive era" is a step-by-step process that cannot be accomplished overnight. Currently in the two important application areas of the Chinese market, one is Real World Evidence, through the cooperation with Pfizer, looking for various medical evidence for the analysis of medical data. We use domestic data to cooperate with domestic advanced medical institutions and pharmaceutical companies. Another area is Continuum of Care disease management. We work with providers of some health services. These health service providers have two appeals. One is how to make my health service provider have a better professional level, to ensure his professional level through cognitive computing technology, and to ensure the quality and safety of treatment. Another point is how to make patients feel more involved, and patients have a better user experience in the medical process.
Some domestic manufacturers have done registration or payment, and the user experience around the extension of medical services has improved, but the real core disease prevention and disease management is still very vacant. Otherwise, it will be found on the Internet before it will happen. False, untrustworthy information. The reason why these things happen, as a user, there is no better channel to obtain authoritative and credible information, so another thing we do is how to make patients better and better access information and improve their self-management ability.
Question: IBM and Pfizer have been working together for a long time. What are the more difficult areas in the cooperation process and how are they overcome?
Gu Chengming : It is important that all cooperation between us and our partners is based on trust. In the process of cooperation, we continue to find greater value, and the sense of trust is gradually increasing. IBM's technology has been formed for many years, the technology we use, the game is used, the competition is also used, these algorithms are similar, but the lack of someone to apply these technologies to the clinic, how to solve the patient's Problems, solving doctors' problems, this is something that people need to do. Everyone's understanding has limitations. I am a digestive professional. I may not have encountered such a problem in surgery. I may not think of it. Now there is a platform. Everyone is doing it on this platform. There will be a very wide application in the future. The more we use, the more we experience and share with each other.
Question: What is the position of the Watson Health Division in the global strategy? In terms of sales and sales, what do you want this business to reach IBM?
Xie Guozhen : IBM has established three departments in cognitive aspects: cognitive medicine, cognitive computing, and cognitive Internet of Things. These three departments are IBM's rapid growth in cognitive computing, and medical care is growing very fast.
Question: The contribution of cognitive computing to innovative drugs in pharmaceutical companies is a driving force. Which stage is the decisive factor in the R&D, clinical and listing stages?
Gu Chengming : R&D, R is research, is a clinical early stage. D is development, is prepared for clinical, the first phase, the second phase, the third phase of the clinical trial to be a two-way comparison, to prove that this drug is better than the current method, or can be listed, and now this piece is also exploring. For example, choose the patient, the same medicine, who is the right patient, and if there is a way to screen out the right patient, the number of samples used will be small. Clinical research Why is this drug better than that? It depends on the gap. A drug with a small gap needs to be enrolled in more people. A small gap is a small number of people who do it. Everyone has money behind it, because it takes millions of dollars to do a registered clinical study. Ten thousand yuan, or even hundreds of millions of yuan, is the same in China, so it is a very expensive process. If it can be shortened, it will save money. More importantly, it is important that the drug can be marketed and the time to market is reduced. If innovative drugs enter the Chinese market faster, more patients will get medical treatment as soon as possible. For example, patients who treat tumors, targeted drugs come in early, many patients avoid losing their lives, which is the value. All aspects have a great role in different periods.
IBM pointed out that the cognitive transformation of enterprises will be a journey, which has five key elements, including: developing a complete cognitive strategy, strengthening cognitive data analysis capabilities, optimizing for industry, data and cognitive APIs. Cloud services to create a platform for new development, optimize the IT infrastructure for cognitive workloads, and ensure data security in a cognitive era. If we can grasp these five key elements, companies can quickly enter the era of cognitive business and successfully embark on the road of transformation.
Source: China Digital Medical Network
Hardware Locks,Stainless Steel Plane Locks,Flat Locks,Plane Locks
Ningbo Hengchieh Locking Technology Co., Ltd. , https://www.hengchieh.com